Skye Bioscience, Inc.

SKYE Nasdaq CIK: 0001516551

Company Information

Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation NV
Business Address 11250 EL CAMINO REAL, SUITE 100, SAN DIEGO, CA, 92130
Mailing Address 11250 EL CAMINO REAL, SUITE 100, SAN DIEGO, CA, 92130
Phone (858) 410-0266
Fiscal Year End 1231
EIN 450692882

Financial Overview

FY2025

$72.76M
Total Assets
$8.29M
Total Liabilities
$-0.73
EPS

Recent SEC Filings

Form Type Date Filed Document
4 Insider stock transaction report April 2, 2026 View on SEC
4 Insider stock transaction report April 2, 2026 View on SEC
4 Insider stock transaction report April 2, 2026 View on SEC
4 Insider stock transaction report April 2, 2026 View on SEC
4 Insider stock transaction report April 2, 2026 View on SEC
4 Insider stock transaction report April 2, 2026 View on SEC
4 Insider stock transaction report April 2, 2026 View on SEC
4 Insider stock transaction report April 2, 2026 View on SEC
8-K Current report of material events March 19, 2026 View on SEC
10-K Annual financial report March 10, 2026 View on SEC

Annual Reports

10-K March 10, 2026
  • Lead drug candidate SBI-100 Ophthalmic Emulsion for glaucoma completed Phase 2 enrollment on schedule by Q3 2025.
  • Secured a key European Union patent covering the formulation and use of SBI-100, strengthening intellectual property.
View Analysis

Material Events

8-K Financial Distress March 19, 2026
High Impact
  • Skye Bioscience is developing new cannabinoid-based medicines for serious conditions like glaucoma and metabolic disorders.
  • The company has a 180-day window (until September 14, 2026) to regain Nasdaq compliance by increasing its stock price.
View Analysis

Related Companies

Companies in the same industry (SIC: 2834)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.